Research programme: siRNA therapeutics - Pfizer/Arbutus Biopharma

Drug Profile

Research programme: siRNA therapeutics - Pfizer/Arbutus Biopharma

Alternative Names: RNAi therapeutics - Arbutus Biopharma/Pfizer; Small interfering RNA therapeutics - Arbutus Biopharma/Pfizer

Latest Information Update: 16 Jul 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Pfizer; Tekmira Pharmaceuticals Corporation
  • Developer Arbutus Biopharma; Pfizer
  • Class Small interfering RNA
  • Mechanism of Action RNA interference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Unspecified

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for research development in Undefined in Canada (Parenteral)
  • 16 Mar 2010 Early research in Undefined indication in Canada (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top